tiprankstipranks
China Resources Pharmaceutical Group Ltd. (DE:640)
FRANKFURT:640
Germany Market

China Resources Pharmaceutical Group Ltd. (640) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

640 Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
China
Resources Pharmaceutical Group Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

640 Stock 12 Month Forecast

There Are No Analyst Ratings for DE:640 In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

640 Financial Forecast

640 Earnings Forecast

Next quarter’s earnings estimate for 640 is €0.03 with a range of €0.03 to €0.03. The previous quarter’s EPS was €0.04. 640 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year 640 has its overall industry.
Next quarter’s earnings estimate for 640 is €0.03 with a range of €0.03 to €0.03. The previous quarter’s EPS was €0.04. 640 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year 640 has its overall industry.

640 Sales Forecast

Next quarter’s sales forecast for 640 is €17.18B with a range of €17.18B to €17.18B. The previous quarter’s sales results were €15.66B. 640 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year 640 has its overall industry.
Next quarter’s sales forecast for 640 is €17.18B with a range of €17.18B to €17.18B. The previous quarter’s sales results were €15.66B. 640 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year 640 has its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guotai Haitong Analyst forecast on DE:640
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
€0.76
Buy
56.04%
Upside
Reiterated
04/20/26
Guotai Haitong Sticks to Its Buy Rating for China Resources Pharmaceutical Group Ltd. (640)
Nomura Analyst forecast on DE:640
Unknown Analyst
Nomura
Not Ranked
Nomura
€0.84
Buy
72.06%
Upside
Reiterated
03/26/26
Nomura Remains a Buy on China Resources Pharmaceutical Group Ltd. (640)
CICC Analyst forecast on DE:640
Unknown Analyst
CICC
Not Ranked
CICC
€0.78
Buy
60.16%
Upside
Reiterated
03/26/26
China Resources Pharmaceutical Group Ltd. (640) Receives a Buy from CICC
China Merchants Securities Analyst forecast on DE:640
Unknown Analyst
China Merchants Securities
Not Ranked
China Merchants Securities
€0.71
Buy
44.14%
Upside
Reiterated
03/26/26
China Merchants Securities Sticks to Its Buy Rating for China Resources Pharmaceutical Group Ltd. (640)
UBS Analyst forecast on DE:640
Unknown Analyst
UBS
Not Ranked
UBS
€0.77
Buy
57.87%
Upside
Reiterated
03/25/26
UBS Keeps Their Buy Rating on China Resources Pharmaceutical Group Ltd. (640)
Bank of America Securities Analyst forecast on DE:640
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
€0.66
Buy
34.99%
Upside
Reiterated
03/25/26
Bank of America Securities Remains a Buy on China Resources Pharmaceutical Group Ltd. (640)
Morgan Stanley Analyst forecast on DE:640
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
€0.76
Buy
55.58%
Upside
Reiterated
10/14/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guotai Haitong Analyst forecast on DE:640
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
€0.76
Buy
56.04%
Upside
Reiterated
04/20/26
Guotai Haitong Sticks to Its Buy Rating for China Resources Pharmaceutical Group Ltd. (640)
Nomura Analyst forecast on DE:640
Unknown Analyst
Nomura
Not Ranked
Nomura
€0.84
Buy
72.06%
Upside
Reiterated
03/26/26
Nomura Remains a Buy on China Resources Pharmaceutical Group Ltd. (640)
CICC Analyst forecast on DE:640
Unknown Analyst
CICC
Not Ranked
CICC
€0.78
Buy
60.16%
Upside
Reiterated
03/26/26
China Resources Pharmaceutical Group Ltd. (640) Receives a Buy from CICC
China Merchants Securities Analyst forecast on DE:640
Unknown Analyst
China Merchants Securities
Not Ranked
China Merchants Securities
€0.71
Buy
44.14%
Upside
Reiterated
03/26/26
China Merchants Securities Sticks to Its Buy Rating for China Resources Pharmaceutical Group Ltd. (640)
UBS Analyst forecast on DE:640
Unknown Analyst
UBS
Not Ranked
UBS
€0.77
Buy
57.87%
Upside
Reiterated
03/25/26
UBS Keeps Their Buy Rating on China Resources Pharmaceutical Group Ltd. (640)
Bank of America Securities Analyst forecast on DE:640
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
€0.66
Buy
34.99%
Upside
Reiterated
03/25/26
Bank of America Securities Remains a Buy on China Resources Pharmaceutical Group Ltd. (640)
Morgan Stanley Analyst forecast on DE:640
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
€0.76
Buy
55.58%
Upside
Reiterated
10/14/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering China Resources Pharmaceutical Group Ltd.

3 Months
Google Health Care EUTipRanks - Google
Success Rate
1/1 ratings generated profit
100%
Average Return
+5.20%
Copying Google Health Care EU's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +5.20% per trade.
1 Year
Google Health Care EUTipRanks - Google
Success Rate
1/1 ratings generated profit
100%
Average Return
+5.20%
Copying Google Health Care EU's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +5.20% per trade.
2 Years
Google Health Care EUTipRanks - Google
Success Rate
1/1 ratings generated profit
100%
Average Return
+5.20%
Copying Google Health Care EU's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +5.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

640 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
5
6
6
1
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
6
6
1
0
In the current month, 640 has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 640 average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

640 Stock Forecast FAQ

What is DE:640’s average 12-month price target, according to analysts?
Currently, no data Available
What is DE:640’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:640, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is China Resources Pharmaceutical Group Ltd. a Buy, Sell or Hold?
      Currently, no data Available
      What is China Resources Pharmaceutical Group Ltd.’s share price target?
      Currently, no data Available
      What do analysts say about China Resources Pharmaceutical Group Ltd.?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of China Resources Pharmaceutical Group Ltd.?
      To buy shares of DE:640, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.